1. Home
  2. PLSE vs ABCL Comparison

PLSE vs ABCL Comparison

Compare PLSE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$47.55

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$12.02

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
ABCL
Founded
2014
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.1B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PLSE
ABCL
Price
$47.55
$12.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
12
Target Price
★ $60.67
$16.82
AVG Volume (30 Days)
419.0K
★ 4.7M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.91
EPS
N/A
★ N/A
Revenue
N/A
★ $75,128,000.00
Revenue This Year
$480.71
N/A
Revenue Next Year
$177.98
$7.12
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 160.56
52 Week Low
$12.56
$2.75
52 Week High
$58.90
$14.98

Technical Indicators

Market Signals
Indicator
PLSE
ABCL
Relative Strength Index (RSI) 44.07 45.97
Support Level $24.27 $11.78
Resistance Level $55.36 $12.88
Average True Range (ATR) 3.15 0.75
MACD -0.78 -0.26
Stochastic Oscillator 31.05 8.65

Price Performance

Historical Comparison
PLSE
ABCL

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: